Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial

Keyphrases

• Older Patients 100%
• Phase I Trial 100%
• Busulfan 100%
• Myeloablative 100%
• Fludarabine 100%
• Long-term Disease 100%
• Prospective Phase II Study 100%
• Disease Outcome 100%
• 95% Confidence Interval 60%
• Hematopoietic Stem Cell Transplantation 30%
• Non-relapse Mortality 30%
• Myeloablative Conditioning 30%
• Acute Myeloid Leukemia 20%
• Myelodysplastic Syndrome 20%
• Myelofibrosis 20%
• Secondary Malignancy 10%
• Hematological Malignancies 10%
• Chemotherapy 10%
• High Risk 10%
• Complete Remission 10%
• Survivors 10%
• 3-year Survival 10%
• Survival Outcomes 10%
• Disease-specific Survival 10%
• Patient Demographics 10%
• Inpatient Treatment 10%
• Prolonged Survival 10%
• Unrelated Donor 10%
• Conditioning Regimen 10%
• Reduced-intensity Conditioning 10%
• Myeloablative Regimen 10%
• Graft-versus-host Disease (GvHD) 10%
• Disease-specific 10%
• Cumulative Incidence 10%
• Bronchiolitis Obliterans 10%
• Area under the Curve 10%
• Once-daily 10%
• Pharmacokinetic Analysis 10%
• Common Diagnoses 10%
• Long-term Complications 10%
• Outpatient Clinic 10%
• Comorbidity Index 10%
• Safe Delivery 10%
• Chronic Graft-versus-host Disease (cGVHD) 10%
• Peripheral Blood Graft 10%
• Average Exposure 10%

Medicine and Dentistry

• Diseases 100%
• Clinical Trial 100%
• Fludarabine 100%
• Busulfan 100%
• Hematopoietic Stem Cell Transplantation 30%
• Non-Relapse Mortality 30%
• Myeloablative Conditioning 30%
• Acute Myeloid Leukemia 20%
• Myelodysplastic Syndrome 20%
• Myelofibrosis 20%
• Cancer 10%
• Overall Survival 10%
• Outpatient 10%
• Disease Specific Survival 10%
• Patient Population 10%
• Comorbidity 10%
• Hematologic Malignancy 10%
• Chemotherapy 10%
• Reduced Intensity Conditioning 10%
• Pharmacokinetic 10%
• Cumulative Incidence 10%
• Graft Versus Host Reaction 10%
• Chronic Graft Versus Host Disease 10%
• Bronchiolitis Obliterans 10%
• Area under the Curve 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Diseases 100%
• Clinical Trial 100%
• Busulfan 100%
• Fludarabine 100%
• Acute Myeloid Leukemia 20%
• Myelodysplastic Syndrome 20%
• Myelofibrosis 20%
• Hematologic Malignancy 10%
• Overall Survival 10%
• Pharmacokinetic 10%
• Remission 10%
• Comorbidity 10%
• Graft Versus Host Reaction 10%
• Chronic Graft Versus Host Disease 10%
• Disease Specific Survival 10%
• Bronchiolitis Obliterans 10%
• Chemotherapy Regimen 10%